Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLRMT | O00411 | 1/20 | 0.37 |
| ▸ | DOT1L | Q8TEK3 | 2/20 | 0.34 |
| ▸ | IARS1 | P41252 | 3/20 | 0.34 |
| ▸ | GSK3A | P49840 | 1/20 | 0.33 |
| ▸ | RPS6KA3 | P51812 | 1/20 | 0.33 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.33 |
| ▸ | SLC5A1 | P13866 | 1/20 | 0.33 |
| ▸ | SLC5A2 | P31639 | 1/20 | 0.33 |
| ▸ | MARS1 | P56192 | 3/20 | 0.33 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.33 |
| ▸ | STING1 | Q86WV6 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26832481 | 0.92 | POLRMT (0.38) | POLRMTDOT1LIARS1GSK3ARPS6KA3 | |
| SCHEMBL26832290 | 0.92 | POLRMT (0.39) | POLRMTDOT1LGSK3ARPS6KA3MAPK14 | |
| SCHEMBL26398893 | 0.90 | POLRMT (0.36) | POLRMTDOT1LGSK3ARPS6KA3MAPK14 | |
| SCHEMBL26832023 | 0.89 | POLRMT (0.40) | POLRMTDOT1LGSK3ARPS6KA3MAPK14 | |
| SCHEMBL26832176 | 0.86 | POLRMT (0.39) | POLRMTDOT1LGSK3ARPS6KA3MAPK14 | |
| SCHEMBL24418856 | 0.84 | SLC5A1 (0.41) | POLRMTDOT1LIARS1GSK3ARPS6KA3 | |
| SCHEMBL26328941 | 0.83 | DOT1L (0.37) | POLRMTDOT1L | |
| SCHEMBL26149119 | 0.82 | POLRMT (0.40) | POLRMTDOT1LGSK3ARPS6KA3MAPK14 | |
| SCHEMBL26148725 | 0.81 | POLRMT (0.39) | POLRMTDOT1LGSK3ARPS6KA3MAPK14 | |
| SCHEMBL26325073 | 0.81 | POLRMT (0.37) | POLRMTDOT1LGSK3ARPS6KA3MAPK14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230382940-A1 | ANTIVIRAL COMPOUNDS AND METHODS OF MAKING AND USING THE SAME | GILEAD SCIENCES, INC. | 2023-11-30 | — | — | US | disclosed |
| US-20230279013-A1 | COMPOUNDS AND METHODS FOR TREATMENT OF VIRAL INFECTIONS | GILEAD SCIENCES, INC. | 2023-09-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230382940-A1 | ANTIVIRAL COMPOUNDS AND METHODS OF MAKING AND USING THE SAME | EIF2AK2, MAVS, ZC3HAV1 | POLRMT 13/4885DOT1L 2954/4885IARS1 381/4885 |
| US-20230279013-A1 | COMPOUNDS AND METHODS FOR TREATMENT OF VIRAL INFECTIONS | HAVCR2, EIF2AK2, OAT | POLRMT 16/4885DOT1L 2112/4885IARS1 1461/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.